Logo
AOD9604 6mg

AOD9604 6mg

AOD9604

Unlicensed peptide for weight management and fat metabolism research / cosmetic use
  • AOD9604 is classified in drug information references as an experimental compound with no approved therapeutic indications; DrugBank and similar databases list it as ‘US Approved: NO’ and ‘Other Approved: NO’, reflecting the absence of marketing authorisations from FDA or other major regulators.
  • The UK MHRA products database does not list any authorised medicinal products containing AOD9604 as an active substance, and there are no UK Product Licence (PL) numbers associated with AOD9604 as a licensed medicine.
  • In the United States, FDA evaluations of AOD 9604 as a bulk drug substance for human drug compounding have identified significant potential safety risks (including immunogenicity concerns and limited safety data), and the substance has been categorised in guidance as inappropriate for compounding for human use.
  • Regulatory commentary on compounded peptides notes AOD 9604 as a substance that should not be compounded for human administration, with the FDA indicating that its nomination for inclusion on bulk drug substance lists should not be accepted due to safety and data concerns.
  • In Australia, medicines Scheduling documents and advisory committee decisions have treated AOD 9604 as a prescription Only substance (e.g. Schedule 4 with inclusion in Appendix D) alongside other growth hormone–related peptides, based on limited risk–benefit information and concerns about misuse; this underscores that AOD9604 is subject to controlled scheduling rather than being an over The Counter supplement.
  • No CE or UKCA medical device certification is associated with AOD9604 6mg; it is not marketed or registered as a medical device, instead appearing only as an investigational / experimental drug candidate or unlicensed peptide product.
  • AOD9604 has been the subject of clinical development programmes by companies such as Metabolic Pharmaceuticals and later Lateral Pharma (for example, under protocol LAT NP 001), but these activities remain within the framework of clinical trials and do not confer approved Medicine status or routine clinical use authorisation.
  • Commercial suppliers commonly label AOD9604 products as being for research or laboratory use only and not for human or veterinary consumption, in alignment with their non Approved regulatory status; any deviation from such use may breach national medicines laws and regulatory guidance.
Synthetic human growth hormone fragment analogue promoted for fat loss and body composition support

Description

AOD9604 6mg is a peptide product sold via dermafillerltd.uk and promoted as an advanced peptide for fat metabolism and weight management support. The product is described in marketing copy as a cutting-edge fat-burning peptide designed to help support weight management, enhance fat metabolism, and promote a leaner physique. It is stated to be a modified fragment of human growth hormone (HGH), targeting fat breakdown while aiming not to affect blood sugar or muscle mass. AOD9604 itself is a synthetic analogue of the C-terminal lipolytic domain of human growth hormone (fragment 177–191) that has been investigated in preclinical and clinical research for obesity and metabolic indications. Experimental work in obese rodents has shown that AOD9604 can reduce body weight and body fat, increase fat oxidation, and stimulate lipolysis, apparently without activating the full growth hormone receptor. Human clinical studies have evaluated AOD9604 as an orally active or peptide-based anti-obesity candidate, but no regulatory authority (including FDA, MHRA, or other major agencies) has granted marketing authorisation for any therapeutic indication. In current commercial practice, AOD9604 6mg vials are sold by peptide vendors and aesthetic / wellness suppliers as research or cosmetic-use products for fat metabolism support, and they are not licensed medicines.

Bnefits

  • Boosts fat metabolism – product marketing describes AOD9604 6mg as helping to accelerate fat breakdown and support weight management by targeting fat metabolism pathways.
  • Promotes lean muscle retention – promotional claims state that AOD9604 is designed to target fat loss while preserving muscle mass, in contrast to non-selective weight-loss strategies.
  • Supports energy and recovery – seller copy suggests that use of AOD9604 may aid in faster recovery and overall vitality as part of a broader lifestyle program.
  • Non-stimulant profile – commercial descriptions emphasise that AOD9604 works without traditional stimulant ingredients (such as sympathomimetic agents), and is promoted as a non-stimulant support for fat loss.
  • Derived from human growth hormone fragment – AOD9604 is a modified analogue of the hGH 177–191 fragment, designed to mimic the lipolytic (fat-regulating) actions of growth hormone without the broader endocrine effects of full-length hGH.
  • Preclinical evidence of lipolytic activity – animal and mechanistic studies show that AOD9604 and related hGH fragments can increase fat oxidation, reduce body fat, and stimulate lipolysis in obese mice and other models, supporting the mechanistic rationale behind its marketing as a fat-metabolism peptide.
  • Investigated in obesity pharmacotherapy research – AOD9604 has been studied in early-phase clinical trials as a candidate obesity treatment, contributing to its positioning by commercial suppliers as a peptide of interest for body composition and weight-management programs.
  • Marketed for integration with healthy lifestyle – the dermafillerltd.uk product text explicitly states that for best results, AOD9604 should be used in conjunction with a healthy lifestyle and that users should consult a healthcare professional before use.

Indications

  • Commercial / cosmetic indication: marketed by dermafillerltd.uk as a peptide to support fat metabolism, weight management, and a leaner physique.
  • Marketed for individuals seeking fat loss, including those with stubborn fat deposits, as described in the seller’s promotional materials.
  • Promoted for athletes and fitness enthusiasts looking to support body composition and performance in conjunction with training and nutrition.
  • Promoted as a potential adjunct for wellness professionals and retailers to include as part of weight-management programmes and body-contouring offerings.
  • Experimental / research context: in the scientific literature, AOD9604 has been investigated as a synthetic analogue of the human growth hormone fragment 177–191 for potential use in obesity and metabolic disorders.
  • No approved therapeutic indication: AOD9604 does not have marketing authorisation from major regulatory agencies such as FDA, MHRA, EMA, or TGA for any human therapeutic use, and is classified as an experimental / investigational compound.
  • In Australia, AOD-9604 has been considered under medicines scheduling frameworks (e.g. Schedule 4, Appendix D) reflecting its status as a prescription-only / controlled substance rather than an over-the-counter cosmetic product; its use outside properly authorised clinical or research settings is restricted.
  • In the United States, FDA evaluations of AOD-9604 as a bulk drug substance for compounding have raised safety concerns (including immunogenicity and limited safety data), and the substance has been placed in a category where compounding for human use is not permitted; thus it is not an approved or permitted active pharmaceutical ingredient for routine medical treatment.

Composition

  • Active substance: AOD9604, a synthetic analogue of the C-terminal lipolytic fragment of human growth hormone (hGH 177–191).
  • Chemical nature: AOD9604 is a 16-amino-acid peptide based on the hGH 177–191 sequence, modified to enhance stability and retain lipolytic activity; it is often described in the literature as Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly with an intramolecular disulphide bridge and a molecular formula around C78H123N23O23S2.
  • Background description from drug databases: AOD9604 is identified as a synthetic analogue of the lipolytic domain of human growth hormone, investigated for obesity and potential osteoporosis indications, and categorised as an experimental compound without any approved indications.
  • Mechanistic profile from preclinical studies: AOD9604 displays lipolytic and anti-lipogenic effects in animal models, including increased fat oxidation, reduced fat mass, and modulation of beta-adrenergic pathway signalling, while not binding the classical growth hormone receptor in the same way as full-length hGH.
  • The dermafillerltd.uk product listing identifies the product as ‘AOD9604 6mg’ but does not publish a complete list of excipients (e.g. buffer components, stabilisers, preservatives) or specify whether the vial contains lyophilised powder or a ready-to-use solution.
  • No official pharmacopoeial monograph or authorised medicinal product composition is available for AOD9604 as a licensed drug in the UK, EU, or US, reflecting its status as an experimental peptide rather than an approved active pharmaceutical ingredient (API).
  • Purity specifications and analytical data (such as exact HPLC purity percentage, residual solvents, or impurity profile) for the specific dermafillerltd.uk AOD9604 6mg product are not publicly listed.
  • No information is publicly provided by dermafillerltd.uk on any additional active substances, preservatives, or formulation enhancers present in the AOD9604 6mg presentation.

Formulation

  • Dosage form (commercial description): AOD9604 6mg is sold as a peptide product for fat metabolism and weight management support; it is typically presented by peptide vendors as a 6 mg vial intended for reconstitution or further preparation, though the dermafillerltd.uk listing does not explicitly state whether the vial is lyophilised powder or solution.
  • Most research and compounding references describe AOD9604 6mg as a lyophilised peptide vial that can be reconstituted with suitable diluent for experimental administration (e.g. in animal models); however, specific instructions and vehicle details for the dermafillerltd.uk product are not disclosed.
  • The concentration after reconstitution (e.g. mg/mL), pH, osmolarity, and exact vehicle composition for this particular commercial product are not publicly listed.
  • No authorised Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), or medical device Instructions for Use (IFU) exists for AOD9604 as a licensed product in the UK, EU, or US; all available formulation information originates from research publications and commercial peptide suppliers rather than regulatory dossiers.
  • AOD9604 has been investigated in clinical studies in oral and other formulations by its original developer (Metabolic Pharmaceuticals and later Lateral Pharma), but these investigational formulations are not identical to the unlicensed 6 mg peptide vials sold by commercial research / cosmetic suppliers.
  • The dermafillerltd.uk listing does not provide information on any antimicrobial preservatives, stabilisers (such as mannitol, trehalose, or amino acids), or buffer systems that may be present in the marketed vials.

Packaging

  • The dermafillerltd.uk site lists AOD9604 6mg as a product in the ‘Weight loss & Fillers’ category, with a sale price (for example, reduced from £25.00 to £20.00) and product image showing a small vial; detailed packaging text is not legible in the publicly available image.
  • Pack size: product category listings indicate AOD9604 6mg as a single unit (one vial) added to the shopping cart; no explicit description of multi-vial packs or kits is provided on the publicly visible pages.
  • No detailed specification is given for the primary container (e.g. clear versus amber glass, stopper material, presence of flip-off cap) or the nature of any secondary packaging such as cartons, inserts, or shrink-wrap.
  • There is no publicly available image of the reverse label or carton showing batch number, expiry date, storage conditions, or regulatory symbols for this dermafillerltd.uk AOD9604 6mg product.
  • No official medicinal packaging information (such as UK PL number, barcodes associated with licensed medicines, or CE/UKCA marks) is associated with the product, which aligns with its status as an unlicensed experimental peptide rather than a regulated medicinal product or medical device.

Usage

  • The product description text provided in the context states: ‘For best results, follow the recommended dosage as part of a healthy lifestyle. Consult with a healthcare professional before use.’ No specific dosing schedule, route of administration, or duration is detailed on the dermafillerltd.uk listing.
  • Commercial and clinic websites that discuss AOD9604 generally describe it as being administered under medical supervision as part of weight-management protocols, often via subcutaneous injection or other routes; however, precise regimens (dose, frequency, treatment length) vary between sources and are not standardised or endorsed by regulatory authorities.
  • In scientific and clinical trial settings, AOD9604 has been administered in structured protocols defined by study designs and ethics approvals; these regimens are specific to the trials and are not general treatment recommendations for the public.
  • Because AOD9604 has no approved therapeutic indication and is classified in drug information databases as an experimental compound, there is no authorised patient or prescriber guidance document (SmPC / PIL) specifying recommended dosing, titration, or monitoring.
  • Many peptide suppliers, including those operating in research markets, explicitly label AOD9604 products as intended for laboratory or research use only and not for human or veterinary consumption; although this specific wording is not fully reproduced on the dermafillerltd.uk AOD9604 6mg page, such caveats reflect the compound’s regulatory status.
  • Users are advised in the provided context to consult a healthcare professional before use, but any use in humans would be off-label, unlicensed, and outside the scope of formal regulatory approval; appropriate medical oversight and compliance with local laws and guidelines are essential.

Contraindications

  • Not publicly listed (no authorised Summary of Product Characteristics or prescribing information exists; AOD9604 is not an approved medicinal product).
  • Regulatory and safety assessments highlight that AOD9604 has limited human safety data and potential risks, including immunogenicity and other safety concerns noted by the FDA; therefore, any use in individuals with significant cardiovascular, metabolic, or immune conditions should only occur, if at all, within rigorously controlled research settings under specialist oversight.
  • Because no formal contraindication list has been approved by any major regulator, potential contraindications must be inferred and assessed by qualified investigators or clinicians within ethically approved clinical trials rather than from standard medicinal labelling.

Adverse Effects

  • Not publicly listed in any authorised medicinal product labelling because AOD9604 is not an approved medicine.
  • Clinical and safety reviews have reported that AOD9604 appeared generally well tolerated in some early clinical studies, with adverse events similar to placebo for short-term administration; however, these findings are limited to specific trial populations and do not constitute comprehensive post-marketing safety data.
  • FDA assessments of AOD9604 as a bulk drug substance for compounding have identified potential significant safety risks, including the possibility of immunogenic reactions and concerns arising from limited and incomplete safety-related information.
  • Reports and commentary relating to regulatory peptide actions (including discussions of peptide bans) have cited AOD9604 among substances for which the FDA lacks sufficient data to determine safety when used in humans and has therefore moved to restrict or prohibit its use in compounded preparations.
  • Some regulatory and scheduling documents (e.g. in Australia) note that growth hormone-related peptides and analogues, including AOD9604, carry uncertain risk–benefit profiles and have been placed under controlled scheduling (such as Schedule 4 with Appendix D) because of potential for misuse, unknown long-term effects, and association with performance enhancement.
  • Because AOD9604 has not undergone the full regulatory approval process for any indication, there is no definitive, regulator-endorsed adverse reaction profile, and long-term or rare adverse effects remain insufficiently characterised.

Storage Conditions

  • The dermafillerltd.uk product page for AOD9604 6mg does not include explicit storage instructions (such as temperature range or protection from light) for this peptide vial.
  • Laboratory and research suppliers of lyophilised peptides similar to AOD9604 typically recommend storing unopened vials in a refrigerator or freezer (for example, 2–8 °C or below −20 °C) in a dry, dark place, and avoiding repeated freeze–thaw cycles after reconstitution; however, such practices are general research-handling guidelines and are not specific, labelled storage instructions for this particular product.
  • No shelf life or expiry period is publicly stated for AOD9604 6mg on dermafillerltd.uk; any expiry date and in-use period would be printed on the physical packaging or vial but are not shown in available online imagery.
  • In the absence of product-specific instructions, it is standard practice for concentrated peptide vials to be kept out of the reach of children, protected from extreme heat and direct sunlight, and handled according to institutional laboratory or clinic protocols for peptide storage, but these points are not explicitly listed in the online product description.

Duration

Not publicly listed (no authorised treatment duration; AOD9604 remains an experimental compound without approved therapeutic regimens, and clinical studies have used varying, trial-specific durations).

Onset

Not publicly listed (no formally established onset-of-action data in approved product literature; available information comes from preclinical and investigational studies rather than licensed labelling).

Browse more Unlicensed peptide for weight management and fat metabolism research / cosmetic use

Top Treatments

Top Cities in the UK